Actively Recruiting
Evaluating GN001 as a Treatment for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia Using Dose Escalation
Led by Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital · Updated on 2026-11-02
42
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating GN001, an investigational lentiviral vector-based treatment that aims to generate CD19-targeted CAR T cells inside the body. This study involves adults aged 18 to 75 years with CD19-positive relapsed or refractory B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia. The main goal is to assess the safety and tolerability of GN001 at various doses while also monitoring antitumor activity and biological responses. Participants receive a single intravenous infusion of GN001 at different dose levels, starting from 1 x 108 TU up to 1 x 109 TU. The study uses a dose-escalation design beginning with accelerated titration and transitioning to a 33 design based on safety criteria. Dose expansion may occur after reviewing safety data. The treatment is administered sequentially across different cohorts. During the study, participants are monitored for dose-limiting toxicities for 28 days after infusion. Researchers will evaluate the expansion and persistence of the CAR T cells and their biological effects. Long-term safety follow-up is planned to continue monitoring participants. The total participation duration extends until the study completion in August 2029.
CONDITIONS
Brief Title
GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here